Novel strategies for relapsed and refractory acute myeloid leukemia

Current Opinion in Hematology

Volumn 15, Issue 2, 2008, Pages 108-114

  Mato, Anthony R ^a   Morgans, Alicia ^a   Luger, Selina M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Leukemia Program   (United States)

Author keywords

Acute myeloid leukemia; Immunotherapy; Reduced intensity conditioning; Refractory acute myeloid leukemia; Relapsed acute myeloid leukemia; Targeted therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLARUBICIN; AP 23573; AZACITIDINE; CLADRIBINE; CYTARABINE; CYTOSINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LESTAURTINIB; MITOXANTRONE; OBLIMERSEN; PREDNISONE; RAPAMYCIN; RETINOIC ACID; TETRANDRINE; TIPIFARNIB; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; IMMUNOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION;

EID: 40049105884     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282f463d2     Document Type: Review

References (43)

1. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332:217-223.
2. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339:1649-1656.
3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903.
4. Litzow MR. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. Curr Opin Hematol 2007; 14:130-137.
5. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075-4083.
6. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002; 43:1715-1727.
7. Robak T, Wrzesie-Ku A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002; 43:281-291.
8. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97:3197-3204.
9. Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: Southwest Oncology Group Study. Leuk Res 1999; 23:787-794.
10. Kern W, Schoch C, Haferlach T, et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000; 14:226-231.
11. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9:1210-1214.
12. Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia-an active and well tolerated regimen. J Clin Oncol 1988; 6:213-217.
13. Herzig RH, Lazarus HM, Wolff SN, et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3:992-997.
14. Lee JH, Choi SJ, Lee JH, et al. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leuk Res 2006; 30:204-210.
15. Giles F, Verstovsek S, Faderl S, et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006; 30:1591-1595. Cloretazine is a promising novel agent in the treatment of advanced AML.
16. Thomas X, Elhamri M, Chelghoum Y, et al. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. Ann Hematol 2005; 84:376-382.
17. Dobashi N, Asai O, Yano S, et al. Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients. Leuk Lymphoma 2006; 47:2203-2207.
18. Wrzesien-Kus A, Robak T, Wierzbowska A, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 2005; 84:557-564.
19. Giles F, Stock W, Vey N, et al. A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine (R) in patients with first relapse of acute myeloid leukemia (AML) [abstract]. Blood 2006; 108:1970.
20. Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006; 107:4614-4622.
21. Roboz GJ, Giles FJ, Ritchie EK, et al. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol 2007; 25:10-15.
22. Stone RM. Novel therapeutic agents in acute myeloid leukemia. Exp Hematol 2007; 35:163-166.
23. Harousseau JL, Lancet JE, Reiffers J, et al. Farnesyltransferase Inhibition Global Human Trials (FIGHT) Acute Myeloid Leukemia Study Group. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007; 109:5151-5156.
24. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100:1532-1542.
25. Levis M, Smith BD, Beran M, et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. Blood 2005; 106:121A.
26. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005; 5:653-661.
27. Rizzieri D, Feldman E, Moore J, et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies [abstract]. Blood 2005; 106:2980.
28. Luger S, Perl A, Kemner A, et al. A phase I dose escalation study of the mTOR inhibitor sirolimus and MEC chemotherapy targeting signal transduction in leukemic stem cells for acute myeloid leukemia. Blood 2006; 108:161.
29. Xu WL, Shen HL, Ao ZF, et al. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 2006; 30:407-413.
30. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108:3271-3279.
31. Garcia-Manero G, Minden M, Estrov Z, et al. A phase I study of the histone deacetylase inhibitor MGCD0103 (MG-0103) given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes (MDS) [abstract]. Blood 2005; 106:239B.
32. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109:2781-2790.
33. Specchia G, Pastore D, Carluccio P, et al. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 2007; 86:425-428.
34. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007; 21:66-71.
35. Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006; 30:777-783.
36. Chevallier P, Milpied N, Hunault-Berger M, et al. MIDAM regimen (Mylotarg + intermediaite dose aracytin + mitoxantrone) is an effective combination of chemo-immunotherapy for relapsed/refractory CD33+ AML patients [abstract]. Blood 2006; 108:1957.
37. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23:4110-4116.
38. Chantry AD, Snowden JA, Craddock C, et al. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant 2006; 12:1310-1317.
39. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26:397-404.
40. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26:1157-1163.
41. Blum W, Bolwell BJ, Phillips G, et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 2006; 12:61-67.
42. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based nonmyeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130:256-264.
43. Sayer HG, Kroger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31:1089-1095.